UOC
ADVM

UBS O'Connor’s Adverum Biotechnologies ADVM Stock Holding History

UBS O'Connor’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,000
Closed -$195K – 391
2020
Q1 		$195K Buy
+2,000
New +$233K ﹤0.01% 301
2015
Q3 		– Sell
-12,739
Closed -$2.07M – 515
2015
Q2 		$2.07M Buy
12,739
+4,689
+58% +$1.58M 0.02% 409
2015
Q1 		$3.26M Buy
+8,050
New +$3.4M 0.03% 337

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS O'Connor's ADVM Position: Q2 2020 in Review

UBS O'Connor sold out of Adverum Biotechnologies (ADVM) in Q2 2020, closing a stake of 2,000 shares — an estimated $195K sold.

UBS O'Connor first reported a position in ADVM in Q1 2015 and held it in 3 quarters. The position peaked at $3.26M in Q1 2015. 141 funds tracked by Wall St. Rank hold ADVM as of Q2 2020.

  • UBS O'Connor reported no remaining Adverum Biotechnologies position as of Q2 2020 after selling out during the quarter.
  • UBS O'Connor sold 2,000 Adverum Biotechnologies shares in Q2 2020, an estimated $195K.
  • UBS O'Connor first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 3 quarters.
  • UBS O'Connor's Adverum Biotechnologies position peaked at $3.26M in Q1 2015.
  • 141 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2020.

Based on UBS O'Connor's 13F filing for Q2 2020, filed 13 Aug 2020.